Literature DB >> 33452499

JAK inhibitors and VTE risk: how concerned should we be?

Stanley B Cohen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33452499     DOI： 10.1038/s41584-021-00575-5

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  2 in total

1.  Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.

Authors:  Mark Yates; Amanda Mootoo; Maryam Adas; Katie Bechman; Sanketh Rampes; Vishit Patel; Sumera Qureshi; Andrew P Cope; Sam Norton; James B Galloway
Journal:  Arthritis Rheumatol       Date:  2020-11-10       Impact factor: 10.995

2.  Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.

Authors:  Stanley B Cohen; Ronald F van Vollenhoven; Kevin L Winthrop; Cristiano A F Zerbini; Yoshiya Tanaka; Louis Bessette; Ying Zhang; Nasser Khan; Barbara Hendrickson; Jeffrey V Enejosa; Gerd R Burmester
Journal:  Ann Rheum Dis       Date:  2020-10-28       Impact factor: 19.103
  2 in total
  2 in total

Review 1.  Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.

Authors:  George Robinson; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808

2.  Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials.

Authors:  Muhammad Haisum Maqsood; Brittany N Weber; Rebecca H Haberman; Kristen I Lo Sicco; Sripal Bangalore; Michael S Garshick
Journal:  ACR Open Rheumatol       Date:  2022-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.